Live tape
Top 8, mentions 7d15,267NVDA6,541 mentions▲ +0.04GOOGL1,865 mentions▲ +0.04SPY1,671 mentions▲ +0.05QQQ1,446 mentions▲ +0.05SPCX1,139 mentions▲ +0.06AMD950 mentions▲ +0.08MSFT842 mentions▲ +0.03CRWV813 mentions▲ +0.07

Equity · Healthcare

PVLA

NASDAQ

Palvella Therapeutics (PVLA)

157 USD +6.08% vs prior close
Palvella Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
2.3B USD
EPS, diluted, year to Dec 2025
−3.71 USD
Next earnings
28 Feb 2027
52-week range
26.46 USD – 157 USD
Avg volume
72.6K

as of Jul 17, 2026

Have Palvella Therapeutics (PVLA) insiders bought or sold shares recently?

In the 90 days to 11 Nov 2026, Palvella Therapeutics insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026.

Form 4, 90 days to 11 Nov 2026, newest reported trade 21 Oct 2026

0buys
10sells
$9.64Mnet sold
4other filings
Have Palvella Therapeutics (PVLA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Oct 2026Goin KathleenChief Operating OfficerSell4,313537K USD
14 Oct 2026JENKINS GEORGE MDirectorSell7,174886K USD
13 Oct 2026JENKINS GEORGE MDirectorSell7,174935K USD
12 Oct 2026JENKINS GEORGE MDirectorSell13,1521.8M USD
16 Sep 2026Goin KathleenChief Operating OfficerSell4,302655K USD
15 Sep 2026JENKINS GEORGE MDirectorSell1,777267K USD
14 Sep 2026JENKINS GEORGE MDirectorSell13,3522.0M USD
11 Sep 2026JENKINS GEORGE MDirectorSell12,3711.9M USD
02 Sep 2026KIRITSY CHRISTOPHER PDirectorSell31349K USD
19 Aug 2026Goin KathleenChief Operating OfficerSell4,302655K USD
Sold10 open-market sales68,230$9.64M
4 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Palvella Therapeutics (PVLA) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
21 Oct 2026Goin KathleenChief Operating OfficerOption exercise4,31335K USD
16 Sep 2026Goin KathleenChief Operating OfficerOption exercise4,30235K USD
02 Sep 2026KIRITSY CHRISTOPHER PDirectorOption exercise31340K USD
19 Aug 2026Goin KathleenChief Operating OfficerOption exercise4,30235K USD

Which funds hold Palvella Therapeutics (PVLA)?

8 of the 45 institutional funds we track reported a Palvella Therapeutics position for the quarter ended 30 Jun 2026 — a combined 27.3M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Palvella Therapeutics (PVLA)?
FundPositionSharesValueShares q/q
Renaissance TechnologiesAdded53,2708.1M USD+196.4%
Millennium ManagementTrimmed52,2128.0M USD−44.2%
Balyasny Asset ManagementTrimmed44,5366.8M USD−54.0%
Two Sigma InvestmentsAdded12,2941.9M USD+151.4%
Tudor Investment CorpNew position7,9061.2M USD
Citadel AdvisorsTrimmed3,520538K USD−82.8%
Marshall WaceNew position2,852436K USD
AQR Capital ManagementNew position2,316354K USD
Point72 Asset ManagementExited

What has been filed or recorded for Palvella Therapeutics (PVLA)?

The filings we hold for Palvella Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 07 Oct 2026. Next report: 28 Feb 2027.

What has been filed or recorded for Palvella Therapeutics (PVLA)?
And
07 Oct 2026Fails to deliverShares failed to deliver3 shares384 USD notional · <0.001% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −1.70 USD
30 Sep 2026FinancialsTotal assets239.4M USDat period end
30 Sep 2026FinancialsTotal equity197.9M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −1.52 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −1.20 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −3.71 USD
31 Dec 2025FinancialsNet income−41.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.71 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −1.03 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.86 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.74 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −7.83 USD

What do people ask about Palvella Therapeutics (PVLA)?

From live data
What is Palvella Therapeutics’ market cap?2.3B

Palvella Therapeutics is worth 2.3B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Palvella Therapeutics insiders bought or sold shares recently?10 sales

In the 90 days to 11 Nov 2026, Palvella Therapeutics insiders reported 10 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 30 Mar 2026. A further 4 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Palvella Therapeutics?8 of 45

8 of the 45 funds we track reported a Palvella Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Millennium Management and Balyasny Asset Management. See Funds

When did Palvella Therapeutics last report earnings?−1.70

Palvella Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −1.70 USD; the next report is scheduled for 28 Feb 2027 (SEC filings). See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings